WO2024088301A1 - 一种棘白素类似物的药物组合物及其制备方法 - Google Patents

一种棘白素类似物的药物组合物及其制备方法 Download PDF

Info

Publication number
WO2024088301A1
WO2024088301A1 PCT/CN2023/126450 CN2023126450W WO2024088301A1 WO 2024088301 A1 WO2024088301 A1 WO 2024088301A1 CN 2023126450 W CN2023126450 W CN 2023126450W WO 2024088301 A1 WO2024088301 A1 WO 2024088301A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
composition according
formula
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
PCT/CN2023/126450
Other languages
English (en)
French (fr)
Inventor
范迎方
叶林茂
陈昊
安东
孟庆庆
姜凯
Original Assignee
江苏恒瑞医药股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 江苏恒瑞医药股份有限公司 filed Critical 江苏恒瑞医药股份有限公司
Publication of WO2024088301A1 publication Critical patent/WO2024088301A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Definitions

  • the present invention belongs to the field of pharmaceutical preparations, and specifically relates to a pharmaceutical composition of an echinocandin analog and a preparation method thereof.
  • amphotericin B a macrolide polyene that interacts with fungal membrane sterols: flucytosine, a fluoropyrimidine that interacts with fungal protein and DNA biosynthesis
  • azole antifungal drugs e.g., ketoconazole, itraconazole, and fluconazole
  • amphotericin B has a broad spectrum of activity and is considered the "gold standard" of antifungal therapy, its use is limited by infusion-related reactions and nephrotoxicity (Warnock, J. Antimicrob.
  • Echinocandins are a new class of antifungal drugs, which usually contain a cyclic hexapeptide and a lipophilic tail, the latter of which is connected to the hexapeptide core via an amide bond.
  • This class of drugs interferes with the synthesis of ⁇ -1,3-glucose in the fungal cell wall by non-competitive inhibition of ⁇ -1,3-glucose synthase, leading to changes in the permeability of the fungal cell wall and cell lysis and death.
  • Anidulafungin is a class of echinocandin drugs, developed by Vicuron Pharmaceuticals in the United States, with the trade name Eraxis, and was approved for marketing in the United States in 2006. Anidulafungin has a broad spectrum of antibacterial activity.
  • CN100335122C discloses a pharmaceutical composition comprising anidulafungin and a micellar-forming surfactant.
  • WO2021110125 discloses a novel structure of an echinocandin drug, such as a compound shown in formula I, which has excellent antibacterial activity.
  • the present disclosure aims to provide a pharmaceutical composition
  • a pharmaceutical composition comprising an active ingredient of a compound represented by formula I or a pharmaceutically acceptable salt thereof, wherein the composition has good formulation stability.
  • the present disclosure provides a pharmaceutical composition, which comprises an active ingredient, a compound represented by formula I or a pharmaceutically acceptable salt thereof, a solubilizer and a buffer, wherein the buffer is selected from glycine, alanine, valine, leucine, isoleucine, phenylalanine, serine, threonine, tyrosine, cysteine, One or more of amino acids, methionine, proline, tryptophan, lysine, arginine, histidine, aspartic acid, glutamic acid, asparagine, glutamine, phosphate, citrate, maleate, borate, carbonate, acetate, lactate, tartrate, malate, succinate, ascorbate, oxalate and sulfate.
  • the buffer is selected from glycine, alanine, valine, leucine, isoleucine, phenylalanine, serine, threonine, tyrosine, cysteine
  • the buffer may be in the form of a free form or a salt form, or a combination of a free form and a salt form.
  • the present disclosure provides a pharmaceutical composition, which comprises an active ingredient, a compound represented by Formula I or a pharmaceutically acceptable salt thereof, a solubilizer and a buffer, wherein the buffer comprises at least one amino acid.
  • the solubilizing agent is selected from one or more of polysorbates, polyoxyethylene castor oil derivatives, polyoxyethylene stearates, sorbitan trioleate, bile salts, and lecithin.
  • the solubilizing agent is a polysorbate, such as polysorbate 20, polysorbate 40, polysorbate 60, or polysorbate 80.
  • the solubilizing agent is beneficial to prevent the active ingredient from precipitating during storage or precipitating in the body after administration, and reduces possible side effects (such as irritation, etc.).
  • the buffer is histidine, including histidine, and a combination of histidine and histidine hydrochloride.
  • the pharmaceutical composition may further comprise a stabilizer, which is selected from one or more of mannitol, sucrose, trehalose, maltose, dextrose and lactose.
  • the stabilizer is mannitol.
  • the pharmaceutical composition may further comprise a pH adjuster, which may be sodium hydroxide, hydrochloric acid, or the like.
  • the compound of Formula I or a pharmaceutically acceptable salt thereof is acetate.
  • the weight ratio of the active ingredient compound represented by formula I or its pharmaceutically acceptable salt to the buffer is 1:0.01-1:5; in certain embodiments, the weight ratio of the active ingredient compound represented by formula I or its pharmaceutically acceptable salt to the buffer is 1:0.05-1:5, and non-limiting examples include: 1:0.01, 1:0.02, 1:0.05, 1:0.1, 1:0.15, 1:0.2, 1:0.25, 1:0.3, 1:0.35, 1:0.4, 1:0.45, 1:0.5, 1:0.6, 1:0.7, 1:0.8, 1:0.9, 1:1, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5, 1:4, 1:4.5, 1:5 or any value between the two.
  • the weight ratio of the active ingredient compound represented by formula I or its pharmaceutically acceptable salt to the buffer is 1:0.02-1:3, for example 1:0.05-1:1, and the ratio of the active ingredient compound represented by formula I or its pharmaceutically acceptable salt to the buffer is appropriate, which is conducive to the stability of the pH of the composition.
  • the weight ratio of the active ingredient compound represented by formula I or its pharmaceutically acceptable salt to the solubilizer is 1:0.1-10; in certain embodiments, the weight ratio of the active ingredient compound represented by formula I or its pharmaceutically acceptable salt to the solubilizer is 1:0.5-5, and non-limiting examples include: 1:1, 1:1.2, 1:1.4, 1:1.5, 1:1.6, 1:1.8, 1:2, 1:2.2, 1:2.4, 1:2.5, 1:2.6, 1:2.8, 1:3, 1:3.2, 1:3.4, 1:3.5, 1:3.6, 1:3.8, 1:4, 1:4.2, 1:4.4, 1:4.5, 1:4.6, 1:4.8, 1:5 or any number between two.
  • the weight ratio of the active ingredient, the compound represented by formula I or a pharmaceutically acceptable salt thereof, to the stabilizer is 1:0.1-10, preferably 1:0.5-5, and non-limiting examples include: 1:0.5, 1:0.6, 1:0.8, 1:0.9, 1:1, 1:1.2, 1:1.4, 1:1.6, 1:1.8, 1:2, 1:2.2, 1:2.4, 1:2.6, 1:2.8, 1:3, 1:3.2, 1:3.4, 1:3.6, 1:3.8, 1:4, 1:4.2, 1:4.4, 1:4.6, 1:4.8, 1:5 or any value in between any two numbers.
  • the pH of the pharmaceutical composition is 4-8. In certain embodiments, the pH of the pharmaceutical composition is 4.5-7. In certain embodiments, the pH of the pharmaceutical composition is 5.5-6.5, non-limiting examples include: 4.5, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0 or any value in between any two numbers.
  • the content of active ingredient or its pharmaceutically acceptable salt in the pharmaceutical composition is 5-300 mg/ml, for example 10-250 mg/ml, and non-limiting examples include: 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250 mg/ml or any value in between any two numbers.
  • the present disclosure also provides a pharmaceutical composition
  • a pharmaceutical composition comprising:
  • the stabilizer is mannitol, wherein the weight ratio of the compound represented by Formula I or its pharmaceutically acceptable salt to the stabilizer buffer is 1:0.5-5;
  • the buffer is histidine, wherein the weight ratio of the compound represented by Formula I or its pharmaceutically acceptable salt to the buffer is 1:0.05-5;
  • the solubilizer is polysorbate, wherein the weight ratio of the compound represented by formula I or its pharmaceutically acceptable salt to the solubilizer is 1:0.5-5;
  • the pH of the composition is 5.5-6.5.
  • composition of the present disclosure may further include other pharmaceutical excipients, such as cosolvents, isotonicity regulators, adsorbents, complexing agents, and the like.
  • pharmaceutical excipients such as cosolvents, isotonicity regulators, adsorbents, complexing agents, and the like.
  • the pharmaceutical composition provided by the present disclosure may be a solid or a liquid, wherein the pharmaceutical composition in solid form is often obtained by freeze-drying a composition in liquid form or can be obtained by reconstitution or reconstitution.
  • the pharmaceutical composition in liquid form may be in the form of a solution or a suspension, preferably in the form of a solution.
  • the liquid composition is obtained by reconstitution or reconstitution of a freeze-dried composition or is a liquid composition before freeze-drying.
  • the solid composition, its reconstitution or reconstitution obtains the aforementioned pharmaceutical composition.
  • the present disclosure provides use of the aforementioned pharmaceutical composition in preparing a medicament for treating and/or preventing fungal infection.
  • the present disclosure provides use of the aforementioned pharmaceutical composition in the preparation of a drug for preventing, stabilizing or inhibiting fungal growth or killing fungi.
  • the pharmaceutical composition provided by the present disclosure is used as a medicament.
  • the medicament can be used to prevent, stabilize or inhibit fungal growth or kill fungi.
  • the present disclosure provides a method for preventing, stabilizing or inhibiting fungal growth or killing fungi, which comprises administering a therapeutically effective amount of the pharmaceutical composition to a patient in need thereof.
  • the present disclosure provides a method for preparing the aforementioned pharmaceutical composition, comprising the step of mixing the compound represented by Formula I or a pharmaceutically acceptable salt thereof with a solubilizer and a buffer.
  • the method further comprises the steps of adjusting pH and lyophilizing.
  • the terms “about” and “approximately” refer to values within an acceptable error range for a specific value determined by a person of ordinary skill in the art, which value depends in part on how it is measured or determined (i.e., the limits of the measurement system). For example, “about” can mean within 1 or more than 1 standard deviation in each practice in the art. Alternatively, “about” or “substantially including” can mean a range of up to 20%. In addition, particularly for biological systems or processes, the term can mean up to an order of magnitude or up to 5 times of a value. Unless otherwise stated, when a specific value appears in the application and claims, the meaning of "about” or “substantially including” should be assumed to be within an acceptable error range for the specific value.
  • the numerical values in this disclosure are instrumental measurements or calculated values after instrumental measurements, and there is a certain degree of error. Generally speaking, plus or minus 10% is within the reasonable error range. Of course, the context in which the numerical value is used needs to be considered.
  • the total impurity content which is a numerical value with an error change of no more than plus or minus 10% after measurement, can be plus or minus 9%, plus or minus 8%, plus or minus 7%, plus or minus 6%, plus or minus 5%, plus or minus 4%, plus or minus 3%, plus or minus 2% or plus or minus 1%, preferably plus or minus 5%.
  • the “weight to volume ratio” described in the present disclosure refers to the weight (in g) of the component contained in every 100 mL of liquid system, that is, g/100 mL.
  • composition 1 increased significantly, and the stability was poor.
  • the pH buffer system of compositions 2 and 3 was histidine and histidine hydrochloride, which could maintain the pH of the solution at 5.5-6.5 after reconstitution.
  • compositions A and B Weigh the excipient Tween 80 and stir it evenly with water for injection until it is dissolved, add the active ingredient and stir to dissolve; weigh the buffer and water for injection, stir to dissolve, mix it evenly with the active ingredient solution, then add mannitol, adjust the pH to 5.5-6.5, filter and sterilize, fill the vials, and freeze-dry to prepare compositions A and B.
  • Example 1 According to the method of Example 1, different buffers were selected according to the composition in Table 6 to prepare comparative compositions, and the pH of the compositions before lyophilization and after reconstitution were measured.
  • Example 1 According to the method of Example 1, according to the composition in Table 7, different contents of auxiliary materials were selected to prepare compositions, and the pH of the compositions before lyophilization and after reconstitution were measured.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本公开提供了一种棘白素类似物的药物组合物及其制备方法。具体的，本公开提供了一种药物组合物，包含式（I）所示化合物或其可药用盐、增溶剂和缓冲剂。该组合物具有优越的稳定性。

Description

一种棘白素类似物的药物组合物及其制备方法
本申请要求申请日为2022/10/25的中国专利申请2022113124878和申请日为2023/07/07的中国专利申请2023108308433的优先权。本申请引用上述中国专利申请的全文。
技术领域
本公开属于药物制剂领域，具体涉及一种棘白素类似物的药物组合物及其制备方法。
背景技术
目前用于治疗真菌感染的可利用的药物包括两性霉素B，一种与真菌膜甾醇相互作用的大环内酯多烯：氟胞嘧啶，一种与真菌蛋白和DNA生物合成相互作用的氟嘧啶，和多种抑制真菌膜-甾醇生物合成的唑类抗真菌药物(例如酮康唑、伊曲康唑，和氟康唑)(Alexander et al.,Drugs,54:657,1997)。即使两性霉素B具有宽的活性范围并被视为抗真菌疗法的“金标准”，其应用因输注相关的反应和肾毒性而受到限制(Warnock,J.Antimicrob.Chemother.,41:95,1998)。由于耐药性微生物的发展及其窄的活性谱，氟胞嘧啶的使用也受到限制。唑类抗真菌药的广泛使用正引起假丝酵母菌种(Candida spp)的临床耐药株的出现。
棘白菌素类药物是一类全新的抗真菌药，其通常包含环状六肽和亲脂性尾部，其中的后者通过酰胺键连接于六肽核心。这类药物通过非竞争性抑制β-1,3-葡萄糖合成酶，干扰真菌细胞壁β-1,3-葡萄糖的合成，导致真菌细胞壁渗透性改变，细胞溶解死亡。由于人类细胞不含有细胞壁，而真菌细胞有细胞壁，棘白菌素类抗真菌药物可直接作用于真菌细胞壁成分，所以该类药对人体的毒性较低，是迄今为止安全性最高的一类抗真菌药物。
阿尼芬净(anidulafungin)是一类棘白菌素类药物，是由美国Vicuron制药公司研制，商品名为Eraxis，2006年在美国获批上市。阿尼芬净具有广谱的抗菌活性。CN100335122C公开了包含阿尼芬净和含有成胶束表面活性剂的药物组合物。
WO2021110125公开了一种新型结构的棘白菌素类药物，如式I所示化合物，该化合物具有优异的抗菌活性，
发明内容
本公开目的在于提供一种包含活性成分式I所示化合物或其可药用盐的药物组合物，该组合物具有良好的制剂稳定性。
本公开提供了一种药物组合物，所述药物组合物包含活性成分式I所示化合物或其可药用盐、增溶剂和缓冲剂，所述缓冲剂选自甘氨酸、丙氨酸、缬氨酸、亮氨酸、异亮氨酸、苯丙氨酸、丝氨酸、苏氨酸、酪氨酸、半胱氨 酸、蛋氨酸、脯氨酸、色氨酸、赖氨酸、精氨酸、组氨酸、天冬氨酸、谷氨酸、天冬酰胺、谷氨酰胺、磷酸盐、柠檬酸盐、马来酸盐、硼酸盐、碳酸盐、醋酸盐、乳酸盐、酒石酸盐、苹果酸盐、琥珀酸盐、抗坏血酸盐、草酸盐和硫酸盐中的一种或多种。
所述缓冲剂的形式可以为游离态或盐的形式，或游离态与盐的组合形式。
本公开提供了一种药物组合物，所述药物组合物包含活性成分式I所示化合物或其可药用盐、增溶剂和缓冲剂，所述缓冲剂包含至少一种氨基酸。
在某些实施方案中，所述增溶剂选自聚山梨醇酯、聚氧乙烯蓖麻油衍生物、聚氧乙烯硬脂酸酯、脱水山梨糖醇三油酸酯、胆汁盐、卵磷脂中的一种或多种。在某些实施方案中，所述增溶剂为聚山梨醇酯，例如聚山梨酯20、聚山梨酯40、聚山梨酯60或聚山梨酯80。所述增溶剂有利于防止活性成分在储存过程中析出或用药后在体内析出，降低可能的副作用反应(例如刺激性等)。
在某些实施方案中，所述缓冲剂为组氨酸，包括组氨酸，以及组氨酸和盐酸组氨酸的组合。
在某些实施方案中，所述药物组合物还可包含稳定剂。所述选自甘露醇、蔗糖、海藻糖、麦芽糖、右旋糖和乳糖中的一种或多种。在某些实施方案中，稳定剂为甘露醇。
在某些实施方案中，所述药物组合物还可包含pH调节剂，所述pH调节剂可以是氢氧化钠、盐酸等。
在某些实施方案中，所述式I所示化合物或其可药用盐为乙酸盐。
在某些实施方案中，所述活性成分式I所示化合物或其可药用盐与缓冲剂的重量比为1:0.01-1:5；在某些实施方案中，所述活性成分式I所示化合物或其可药用盐与缓冲剂的重量比为1:0.05-1:5，非限制性实施例包括：1:0.01、1:0.02、1:0.05、1:0.1、1:0.15、1:0.2、1:0.25、1:0.3、1:0.35、1:0.4、1:0.45、1:0.5、1:0.6、1:0.7、1:0.8、1:0.9、1:1、1:1.5、1:2、1:2.5、1:3、1:3.5、1:4、 1:4.5、1:5或任意两者数之间任意值。在某些实施方案中，所述活性成分式I所示化合物或其可药用盐与缓冲剂的重量比为1:0.02-1:3，例如1:0.05-1:1，所述活性成分式I所示化合物或其可药用盐与缓冲剂的比例合适，有利于组合物pH的稳定。
在某些实施方案中，所述活性成分式I所示化合物或其可药用盐与增溶剂的重量比为1:0.1-10；在某些实施方案中，所述活性成分式I所示化合物或其可药用盐与增溶剂的重量比为1:0.5-5，非限制性实施例包括：1:1、1:1.2、1:1.4、1:1.5、1:1.6、1:1.8、1:2、1:2.2、1:2.4、1:2.5、1:2.6、1:2.8、1:3、1:3.2、1:3.4、1:3.5、1:3.6、1:3.8、1:4、1:4.2、1:4.4、1:4.5、1:4.6、1:4.8、1:5或任意两者数之间任意。
在某些实施方案中，所述活性成分式I所示化合物或其可药用盐与稳定剂的重量比为1:0.1-10，优选1:0.5-5，非限制性实施例包括：1:0.5、1:0.6、1:0.8、1:0.9、1:1、1:1.2、1:1.4、1:1.6、1:1.8、1:2、1:2.2、1:2.4、1:2.6、1:2.8、1:3、1:3.2、1:3.4、1:3.6、1:3.8、1:4、1:4.2、1:4.4、1:4.6、1:4.8、1:5或任意两者数之间任意值。
在某些实施方案中，所述药物组合物的pH为4-8。在某些实施方案中，所述药物组合物的pH为4.5-7。在某些实施方案中，所述药物组合物的pH为5.5-6.5，非限制性实施例包括：4.5、5.0、5.1、5.2、5.3、5.4、5.5、5.6、5.7、5.8、5.9、6.0、6.1、6.2、6.3、6.4、6.5、6.6、6.7、6.8、6.9、7.0或任意两者数之间任意值。
在某些实施方案中，药物组合物中活性成分或其可药用盐的含量为5-300mg/ml，例如10-250mg/ml，非限制实施例包括：10、15、20、25、30、35、40、45、50、55、60、65、70、75、80、85、90、95、100、105、110、115、120、125、130、135、140、145、150、155、160、165、170、175、180、185、190、195、200、205、210、215、220、225、230、235、240、245、250mg/ml或任意两者数之间任意值。
本公开还提供了一种药物组合物，其包含：
5-300mg/ml的式I所示化合物或其可药用盐；
稳定剂为甘露醇，其中所述式I所示化合物或其可药用盐与稳定剂缓冲剂为的重量比为1:0.5-5；
缓冲剂为组氨酸，其中所述式I所示化合物或其可药用盐与缓冲剂的重量比为1:0.05-5；
增溶剂为聚山梨醇酯，其中式I所示化合物或其可药用盐与增溶剂的重量比为1:0.5-5；
以及任选的pH调节剂，
其中所述组合物的pH为5.5-6.5。
本公开药物组合物还可以进一步包含其他的药用辅料，例如助溶剂、等渗调节剂、吸附剂、络合剂等。
本公开提供的药物组合物可以是固体，也可以是液体，其中固体形式的药物组合物往往是通过冻干液体形式的组合物得到或者说经过复溶或重构可以得到液体形式的组合物。液体形式的药物组合物可以为溶液形式、混悬液形式，优选为溶液形式。在某些实施方案中，液体组合物是由冻干组合物复溶或重构得到或者是冻干前的液体组合物。在某些实施方案中，固体组合物，其复溶或重构得到前述药物组合物。
本公开提供的前述药物组合物在制备治疗和/或预防真菌感染的药物中的用途。
本公开提供的前述药物组合物在制备用于预防、稳定或抑制真菌生长或杀死真菌的药物中的用途。
本公开提供的药物组合物用作药物。所述药物可用于预防、稳定或抑制真菌生长或杀死真菌。
本公开提供了一种预防、稳定或抑制真菌生长或杀死真菌的方法，其包括向需要其的患者施用治疗有效量的所述药物组合物。
本公开提供一种制备前述药物组合物的方法，包括将式I所示化合物或其可药用盐与增溶剂和缓冲剂混合的步骤。
在某些实施方案中，还进一步包括调节pH和冻干的步骤。
本文所用术语“约”、“大约”是指数值在由本领域一般技术人员所测定的具体值的可接受误差范围内，所述数值部分取决于怎样测量或测定(即测量体系的限度)。例如，在本领域每一次实行中“约”可意味着在1内或超过1的标准差。或者，“约”或“基本上包含”可意味着至多20％的范围。此外，特别对于生物学系统或过程而言，该术语可意味着至多一个数量级或数值的至多5倍。除非另外说明，否则当具体值在本申请和权利要求中出现时，“约”或“基本上包含”的含义应该假定为在该具体值的可接受误差范围内。
本公开中数值为仪器测量值或仪器测量后计算值，存在一定程度的误差，一般而言，正负10％均属于合理误差范围内。当然需要考虑该数值所用之处的上下文，例如，总杂质的含量，该数值为测量后误差变化不超过正负10％，可以为正负9％、正负8％、正负7％、正负6％、正负5％、正负4％、正负3％、正负2％或正负1％，优选正负5％。
本公开所述的“重量体积比”是指每100mL液体体系中含有所述成分的重量(单位g)，即g/100mL。
具体实施方式
通过以下实施例进一步详细说明本公开。这些实施例仅用于说明性目的，而并不用于限制本公开的范围。
实施例所述的式I所示化合物的乙酸盐的含量以式I所示化合物的游离态计。
实施例1缓冲剂筛选实验
实验方法：称取辅料吐温80与注射用水搅拌均匀至溶解，加入活性成分搅拌溶解；称取缓冲剂与注射用水，搅拌溶解，与活性成分药液混合均 匀，再与加入甘露醇，调节pH至5.5-6.5，过滤除菌，灌装西林瓶，冷冻干燥，分别制备组合物2和3。
表1各组合物组分
测试结论：组合物1在冻干后，pH大幅升高，稳定性差。组合物2和3的pH缓冲体系为组氨酸和盐酸组氨酸，可以使复溶后溶液pH维持在5.5-6.5。
表2缓冲剂筛选结果
实施例2：制剂稳定性
称取辅料吐温80与注射用水搅拌均匀至溶解，加入活性成分搅拌溶解；称取缓冲剂与注射用水，搅拌溶解，与活性成分药液混合均匀，再与加入甘露醇，调节pH至5.5-6.5，过滤除菌，灌装西林瓶，冷冻干燥，制备组合物A和B。
表3各组合物组分

实验设计及方案：对组合物A和B进行了影响因素实验，考察了温度(40℃±2℃/RH75％±5％)，冻融循环(-20℃2天，25℃2天为1个循环)以及光照对本品的影响。具体的方案参见表4，所得结果参见表5。
表4.影响因素实验方案
表5.1影响因素试验结果-高温结果
注：“/”表示该项在该点未检测。
表5.2影响因素试验结果-冻融循环结果

注：“/”表示该项在该点未检测。
表5.3影响因素试验结果--光照结果(组合物A)
注：“/”表示该项在该点未检测。
表5.4影响因素试验结果--光照结果(组合物B)
注：“/”表示该项在该点未检测。
实验结论：各组合物在各影响因素测试条件下稳定性良好。
实施例3
根据实施例1的方法，按照表6的组成，选择不同的缓冲剂，制备对比组合物，并测定冻干前和复溶后的组合物pH。
表6组合物组成

实验结论：采用其他类型的pH缓冲剂，对组合物pH的缓冲效果均不及组氨酸。
实施例4
根据实施例1的方法，按照表7的组成，选择不同含量的辅料制备组合物，并测定冻干前和复溶后的组合物pH。
表7组合物组成
实验结论：各组合物pH的缓冲效果均较好。

Claims (19)

  1. 一种药物组合物，包含式I所示化合物或其可药用盐、增溶剂和缓冲剂，所述缓冲剂选自甘氨酸、丙氨酸、缬氨酸、亮氨酸、异亮氨酸、苯丙氨酸、丝氨酸、苏氨酸、酪氨酸、半胱氨酸、蛋氨酸、脯氨酸、色氨酸、赖氨酸、精氨酸、组氨酸、天冬氨酸、谷氨酸、天冬酰胺、谷氨酰胺、磷酸盐、柠檬酸盐、马来酸盐、硼酸盐、碳酸盐、醋酸盐、乳酸盐、酒石酸盐、苹果酸盐、琥珀酸盐、抗坏血酸盐、草酸盐和硫酸盐中的一种或多种，更优选为组氨酸，
  2. 根据权利要求1所述的药物组合物，其中所述增溶剂选自聚山梨醇酯、聚氧乙烯蓖麻油衍生物、聚氧乙烯硬脂酸酯、脱水山梨糖醇三油酸酯、胆汁盐、卵磷脂中的一种或多种，优选聚山梨醇酯。
  3. 根据权利要求1或2所述的药物组合物，其中还包含稳定剂，所述稳定剂优选自甘露醇、蔗糖、海藻糖、麦芽糖、右旋糖和乳糖中的一种或多种，更优选甘露醇。
  4. 根据权利要求1-3任意一项所述的药物组合物，其中还包含pH调节剂。
  5. 根据权利要求1-4任意一项所述的药物组合物，其中所述式I所示化合物或其可药用盐为乙酸盐。
  6. 根据权利要求1-5任意一项所述的药物组合物，其中所述式I所示化 合物或其可药用盐与缓冲剂的重量比为1:0.01-5，优选1:0.05-5。
  7. 根据权利要求1-6任意一项所述的药物组合物，其中所述式I所示化合物或其可药用盐与增溶剂的重量比为1:0.1-10，优选1:0.5-5。
  8. 根据权利要求1-7任意一项所述的药物组合物，其中所述式I所示化合物或其可药用盐与稳定剂的重量比为1:0.1-10，优选1:0.5-5。
  9. 根据权利要求1-8中任意一项所述的药物组合物，其中所述组合物的pH为4-8，优选4.5-7，更优选为5.5-6.5。
  10. 根据权利要求1-9中任意一项所述的药物组合物，其中式I所示化合物或其可药用盐的含量为5-300mg/ml，优选10-250mg/ml。
  11. 一种药物组合物，其包含：
    5-300mg/ml的式I所示化合物或其可药用盐；
    稳定剂为甘露醇，其中所述式I所示化合物或其可药用盐与稳定剂为的重量比为1:0.5-5；
    缓冲剂为组氨酸，其中所述式I所示化合物或其可药用盐与缓冲剂的重量比为1:0.05-5；
    增溶剂为聚山梨醇酯，其中式I所示化合物或其可药用盐与增溶剂的重量比为1:0.5-5；
    以及任选的pH调节剂，
    其中所述组合物的pH为5.5-6.5。
  12. 根据权利要求1-11中任意一项所述的药物组合物，其为液体组合物。
  13. 一种固体组合物，其复溶或重构可得到权利要求1-12所述的药物组合物。
  14. 一种冻干组合物，其中所述冻干组合物通过将权利要求1至12中任一项所述的药物组合物冷冻干燥获得。
  15. 一种复溶溶液，其中所述复溶溶液是通过将权利要求13所述的固体组合物或权利要求14所述的冻干组合物复溶制备获得。
  16. 根据权利要求1至12中任一项所述的药物组合物、根据权利要求13所述的固体组合物、根据权利要求14所述的冻干组合物或根据权利要求15所述的复溶溶液在制备治疗和/或预防真菌感染的药物中的用途。
  17. 根据权利要求1至12中任一项所述的药物组合物、根据权利要求13所述的固体组合物、根据权利要求14所述的冻干组合物或根据权利要求15所述的复溶溶液在制备用于预防、稳定或抑制真菌生长或杀死真菌的药物中的用途。
  18. 一种制备如权利要求1-13所述的药物组合物的方法，包括：将式I所示化合物或其可药用盐与增溶剂和缓冲剂混合的步骤。
  19. 根据权利要求18所述的方法，还进一步包括冻干的步骤。
PCT/CN2023/126450 2022-10-25 2023-10-25 一种棘白素类似物的药物组合物及其制备方法 WO2024088301A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202211312487.8 2022-10-25
CN202211312487 2022-10-25
CN202310830843 2023-07-07
CN202310830843.3 2023-07-07

Publications (1)

Publication Number Publication Date
WO2024088301A1 true WO2024088301A1 (zh) 2024-05-02

Family

ID=90830027

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/126450 WO2024088301A1 (zh) 2022-10-25 2023-10-25 一种棘白素类似物的药物组合物及其制备方法

Country Status (2)

Country Link
TW (1) TW202426032A (zh)
WO (1) WO2024088301A1 (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103861083A (zh) * 2012-12-14 2014-06-18 上海医药工业研究院 一种更稳定的棘白菌素类抗真菌剂的药用组合物
WO2017049102A1 (en) * 2015-09-16 2017-03-23 Cidara Therapeutics, Inc. Methods for treating fungal infections
CN114616238A (zh) * 2019-12-06 2022-06-10 上海森辉医药有限公司 棘白菌素类似物及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103861083A (zh) * 2012-12-14 2014-06-18 上海医药工业研究院 一种更稳定的棘白菌素类抗真菌剂的药用组合物
WO2017049102A1 (en) * 2015-09-16 2017-03-23 Cidara Therapeutics, Inc. Methods for treating fungal infections
CN114616238A (zh) * 2019-12-06 2022-06-10 上海森辉医药有限公司 棘白菌素类似物及其制备方法

Also Published As

Publication number Publication date
TW202426032A (zh) 2024-07-01

Similar Documents

Publication Publication Date Title
US7198796B2 (en) Antifungal parenteral products
US9393307B2 (en) Caspofungin composition
US8980827B2 (en) Medicinal composition containing echinocandin antifungal agent micafungin and preparation method and use thereof
US9662342B2 (en) Formulations of cyclophosphamide liquid concentrate
JP6832281B2 (ja) バンコマイシンの水溶液製剤
US20150073000A1 (en) Stable ready-to-use pharmaceutical composition of pemetrexed
WO2024088301A1 (zh) 一种棘白素类似物的药物组合物及其制备方法
CN111840511A (zh) 一种含有精氨酸的达托霉素或其盐的组合物
WO2018184540A1 (zh) 包含组氨酸缓冲体系的英夫利西单抗组合物
US20230068866A1 (en) Daptomycin formulation
CN106619541A (zh) 艾沙康唑鎓硫酸盐冻干粉针剂及制备方法
CN116251168A (zh) 一种棘白素类似物的药物组合物及其制备方法
WO2019047812A1 (zh) 多西他赛共缀物的药物组合物及制备方法
WO2017037232A1 (en) Anidulafungin formulations
WO2017198224A1 (zh) 一种瑞马唑仑的药物组合物
US20140275122A1 (en) Voriconazole Formulations
EP1663296A1 (en) Liquid human growth hormone formulation containing polyethylene glycol
TW202416947A (zh) 液體達巴萬星組成物
KR20240080282A (ko) 두타스테리드를 포함하는 서방성 제제 및 그 제조방법
NZ773548A (en) Stable intranasal formulations of carbetocin
EP3220954A2 (en) Process for preparation of parenteral formulation of anidulafungin
CN108272755A (zh) 一种注射用盐酸吗替麦考酚酯冻干制剂及其制备方法
TW201302755A (zh) 含胺基酸穩定劑的替莫唑胺醫藥組成物及其製備方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23881878

Country of ref document: EP

Kind code of ref document: A1